An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential

An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential

Background—Doxorubicin (DOXO) is an effective anthracycline chemotherapeutic, but its use is limited by cumulative dose-dependent cardiotoxicity. Neuregulin-1β is an ErbB receptor family ligand that is effective against DOXO-induced cardiomyopathy in experimental models but is also proneoplastic. We...

Full description

Bibliographic Details
Main Authors: Jay, Steven M., Murthy, Ashwin C., Hawkins, Jessica F., Wortzel, Joshua R., Steinhauser, Matthew L., Alvarez, Luis M., Gannon, Joseph, Macrae, Calum A., Griffith, Linda G., Lee, Richard T.
Other Authors: Massachusetts Institute of Technology. Center for Gynepathology Research
Format: Article
Language:en_US
Published: American Heart Association 2014
Online Access:http://hdl.handle.net/1721.1/88965
https://orcid.org/0000-0002-1801-5548

Internet

http://hdl.handle.net/1721.1/88965
https://orcid.org/0000-0002-1801-5548

Similar Items